Give patients greater nasal symptom relief than they get with Flonase®

Give Patients Greater Nasal Symptom Relief Than They Get With FLONASE

  • With the same anti-inflammatory as Flonase® plus an antihistamine, Dymista provides onset of nasal symptom relief as fast as 00:30 minutes vs placebo (P<.05)

The fluticasone propionate-containing comparator used the same device and vehicle as Dymista and is not commerically marketed.1

First timepoint (30 minutes) at which Dymista significantly improved, and continued to improve, seasonal nasal allergy symptoms vs placebo in patients 12 years and older.1

Total nasal symptom score is calculated as the sum of the patients' scoring of the 4 individual nasal symptoms (rhinorrhea, congestion, sneezing, and itching) on a 0-to-3 categorical severity scale (0=absent, 1=mild, 2=moderate, 3=severe).1

Flonase® and Dymista may not be comparable in terms of efficacy and safety.

References: 1. Dymista [package insert]. Somerset, NJ: Meda Pharmaceuticals Inc., a Mylan Company; 2015. 2. Carr W, Bernstein J, Lieberman P, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012;129(5):1282-1289.e10. 3. Flonase [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2015.


  • Somnolence: Avoid engaging in hazardous occupations requiring complete mental alertness such as driving or operating machinery when taking DYMISTA.
  • Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with DYMISTA because further decreased alertness and impairment of CNS performance may occur.
  • Epistaxis, nasal ulcerations, nasal septal perforation, impaired wound healing, Candida albicans infection: Monitor patients periodically for signs of adverse effects on the nasal mucosa. Avoid use in patients with recent nasal ulcers, nasal surgery, or nasal trauma.
  • Glaucoma or posterior subcapsular cataracts: Monitor patients closely with a change in vision or with a history of increased intraocular pressure, glaucoma, and/or cataracts.
  • Potential worsening of existing tuberculosis, fungal, bacterial, viral, or parasitic infections, or ocular herpes simplex. More serious or even fatal course of chickenpox or measles in susceptible patients. Use caution in patients with the above because of the potential for worsening of these infections.
  • Hypercorticism and adrenal suppression with very high dosages or at the regular dosage in susceptible individuals. If such changes occur, discontinue DYMISTA slowly.
  • Potential reduction in growth velocity in children. Monitor growth routinely in pediatric patients receiving DYMISTA.
  • Potent inhibitors of cytochrome P450 (CYP) 3A4: May increase blood levels of fluticasone propionate.
  • Ritonavir: Coadministration is not recommended.
  • Other potent CYP3A4 inhibitors, such as ketoconazole: use caution with coadministration.
  • The most common adverse reaction (≥2% incidence) are dysgeusia, epistaxis, and headache.


DYMISTA contains an H1-receptor antagonist and a corticosteroid, and is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 6 years of age and older who require treatment with both azelastine hydrochloride and fluticasone propionate for symptom relief.

Please see the Full Prescribing Information.

Flonase is a registered trademark of GlaxoGroup Limited. Dymista and Astelin are registered trademarks of Meda Pharmaceuticals Inc., a Mylan Company. The Mylan logo is a registered trademark of Mylan Inc. All other trademarks and service marks are the property of their respective owners. The website is intended for residents of the United States who will prescribe or fill prescriptions for patients located within the United States.
© 2017 Mylan Specialty L.P. All rights reserved.